Sagimet Biosciences Series Stock Analysis

SGMT Stock   4.39  0.15  3.30%   
Sagimet Biosciences Series is undervalued with Real Value of 13.96 and Target Price of 43.33. The main objective of Sagimet Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Sagimet Biosciences Series is worth, separate from its market price. There are two main types of Sagimet Biosciences' stock analysis: fundamental analysis and technical analysis.
The Sagimet Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Sagimet Biosciences is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Sagimet Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sagimet Biosciences Series. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Sagimet Stock Analysis Notes

About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.83. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sagimet Biosciences recorded a loss per share of 0.92. The entity had not issued any dividends in recent years. To find out more about Sagimet Biosciences Series contact David Happel at 650 561 8600 or learn more at https://www.sagimet.com.

Sagimet Biosciences Investment Alerts

Sagimet Biosciences is way too risky over 90 days horizon
Sagimet Biosciences appears to be risky and price may revert if volatility continues
Sagimet Biosciences has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 2 M. Net Loss for the year was (27.88 M) with profit before overhead, payroll, taxes, and interest of 0.
Sagimet Biosciences generates negative cash flow from operations
Sagimet Biosciences has a frail financial position based on the latest SEC disclosures
About 70.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Sagimet Biosciences SWOT analysis promising NASH drug faces funding hurdles

Sagimet Biosciences Upcoming and Recent Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Sagimet Largest EPS Surprises

Earnings surprises can significantly impact Sagimet Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-14
2024-06-30-0.33-0.250.0824 
2024-05-15
2024-03-31-0.4-0.230.1742 
2024-03-25
2023-12-31-0.58-0.78-0.234 
View All Earnings Estimates

Sagimet Biosciences Environmental, Social, and Governance (ESG) Scores

Sagimet Biosciences' ESG score is a quantitative measure that evaluates Sagimet Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Sagimet Biosciences' operations that may have significant financial implications and affect Sagimet Biosciences' stock price as well as guide investors towards more socially responsible investments.

Sagimet Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 191.24 M.

Sagimet Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.29)(0.30)
Return On Capital Employed(0.34)(0.35)
Return On Assets(0.29)(0.30)
Return On Equity(0.31)(0.29)

Management Efficiency

Sagimet Biosciences has return on total asset (ROA) of (0.2154) % which means that it has lost $0.2154 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2932) %, meaning that it created substantial loss on money invested by shareholders. Sagimet Biosciences' management efficiency ratios could be used to measure how well Sagimet Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.35 in 2024. Total Current Liabilities is likely to drop to about 3.8 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 59.2 M in 2024
Last ReportedProjected for Next Year
Book Value Per Share 8.71  9.14 
Tangible Book Value Per Share 8.71  9.14 
Enterprise Value Over EBITDA 0.60  0.63 
Price Book Value Ratio 0.62  0.65 
Enterprise Value Multiple 0.60  0.63 
Price Fair Value 0.62  0.65 
Enterprise Value-18.4 M-17.5 M
Sagimet Biosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin
(18.14)
Return On Assets
(0.22)
Return On Equity
(0.29)

Technical Drivers

As of the 15th of December 2024, Sagimet Biosciences has the Coefficient Of Variation of 1090.38, risk adjusted performance of 0.0753, and Semi Deviation of 4.9. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sagimet Biosciences, as well as the relationship between them.

Sagimet Biosciences Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Sagimet Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Sagimet Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Sagimet Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sagimet Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sagimet Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sagimet Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Sagimet Biosciences Predictive Daily Indicators

Sagimet Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sagimet Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Sagimet Biosciences Corporate Filings

10Q
14th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
16th of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
15th of August 2024
Other Reports
ViewVerify
10Q
14th of August 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
F3
5th of August 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
8K
1st of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
25th of July 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
23rd of July 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Sagimet Biosciences Forecast Models

Sagimet Biosciences' time-series forecasting models are one of many Sagimet Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sagimet Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Sagimet Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Sagimet Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sagimet shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Sagimet Biosciences. By using and applying Sagimet Stock analysis, traders can create a robust methodology for identifying Sagimet entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(12.54)(13.17)
Operating Profit Margin(13.83)(14.52)
Net Loss(12.54)(13.17)

Current Sagimet Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sagimet analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sagimet analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
43.33Strong Buy8Odds
Sagimet Biosciences Series current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Sagimet analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Sagimet stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Sagimet Biosciences, talking to its executives and customers, or listening to Sagimet conference calls.
Sagimet Analyst Advice Details

Sagimet Stock Analysis Indicators

Sagimet Biosciences Series stock analysis indicators help investors evaluate how Sagimet Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Sagimet Biosciences shares will generate the highest return on investment. By understating and applying Sagimet Biosciences stock analysis, traders can identify Sagimet Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow158 K
Common Stock Shares Outstanding10.5 M
Total Stockholder Equity91.1 M
Property Plant And Equipment Net73 K
Cash And Short Term Investments94.9 M
Cash75.1 M
Accounts Payable186 K
Net Debt-75.1 M
50 Day M A4.3079
Total Current Liabilities5.7 M
Other Operating Expenses32.7 M
Non Current Assets Total73 K
Stock Based CompensationM

Additional Tools for Sagimet Stock Analysis

When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.